HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forest Cuts Combunox Detailing Following Disappointing Launch

This article was originally published in The Pink Sheet Daily

Executive Summary

Forest plans to reassign the combination pain therapy’s 1,100-person sales force to detail Lexapro, Namenda and the launch of nebivolol, pending FDA approval.
Advertisement

Related Content

Mylan Finds Its Way Out Of The Woods: Forest Signs Nebivolol Licensing Agreement
Combunox's Future At Forest May Depend On Success Of New Trial Program
Combunox's Future At Forest May Depend On Success Of New Trial Program

Topics

Advertisement
UsernamePublicRestriction

Register

PS063044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel